CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Apollo Therapeutics, the portfolio biopharmaceutical company, today announces positive results from its 32-week CHAMELEON phase 2a clinical trial of ...
Last participant has been randomized and dosed in the Phase 3 APOLLO study of bitopertin in erythropoietic protoporphyria (EPP) The study size was expanded to 183 participants due to patient and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results